Jingfeng Pharmaceutical Letrozole Tablets Obtained Drug Registration Approval

On June 10, Jingfeng Pharmaceutical issued an announcement stating that its subsidiary Hainan Jinrui Pharmaceutical had obtained the "Drug Registration Approval Document" for the chemical drug "Letrozole Tablets" approved and issued by the State Drug Administration
.

It is reported that letrozole is a selective, non-steroidal aromatase inhibitor, which has no negative effects on the secretion of glucocorticoids and mineralocorticoids and thyroid function
.
It can competitively bind to the heme of the cytochrome P450 enzyme subunit, thereby inhibiting aromatase, leading to a decrease in the biosynthesis of estrogen in all tissues

The drug is mainly used for adjuvant treatment of patients with early postmenopausal breast cancer who have received tamoxifen for 5 years, or adjuvant treatment for patients with early postmenopausal breast cancer who are positive for estrogen or progesterone receptors
.
It is also suitable for the treatment of postmenopausal, estrogen receptor-positive, progesterone-receptor-positive, or advanced breast cancer patients whose receptor status is unknown.